PrihodDobitKGVKUVEBITDividendaDioniceTržišna kapitalizacijaDugovanjeObvezeTemeljni kapitalAAQSzaposleniciROEROAROCE
Vir Biotechnology Dionica

Vir Biotechnology Temeljni kapital 2024

Vir Biotechnology Temeljni kapital

1,59 milijardi USD

Ticker

VIR

ISIN

US92764N1028

WKN

A2PS0P

U godini 2024 vlasnički kapital poduzeća Vir Biotechnology iznosio je 1,59 milijardi USD, porast za −23,47% u usporedbi s 2,08 milijardi USD vlasničkim kapitalom prethodne godine.

Vir Biotechnology Aktienanalyse

Što radi Vir Biotechnology?

Vir Biotechnology Inc. is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company was founded in 2016 by George Scangos, former CEO of Biogen, and Bob Nelsen, co-founder of Arch Venture Partners. History: Vir Biotechnology originated from a collaboration between Arch Venture Partners and the biotechnology incubator, The Infectious Disease Research Institute (IDRI), to develop therapeutics against Ebola viruses. In 2016, they founded Vir Biotechnology with an initial capital of $150 million from various investors, including SoftBank and the Bill & Melinda Gates Foundation. The company received an additional capital injection of $250 million in 2018 and went public in the same year. Business model: Vir Biotechnology builds on its proprietary technology platform, which focuses on antibody identification. The company collaborates with various partners, including Biogen and Alnylam Pharmaceuticals, to utilize its technology for the development of therapeutics against infectious diseases such as COVID-19, influenza, rabbit fever, and the Zika virus. Vir Biotechnology also has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482. VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19 and is currently in phase 3 clinical trials. VIR-2703 is an inactive RNA vaccine developed for the prevention of COVID-19 and is currently in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine recently investigated in a phase 1/2a clinical trial. Divisions: Vir Biotechnology has focused on three main divisions: infectious diseases, immuno-oncology therapy, and neurodegenerative diseases. In the field of infectious diseases, the company works on the development of therapeutics against viruses such as COVID-19, respiratory syncytial virus (RSV), West Nile virus, and influenza virus. In the field of immuno-oncology therapy, the company works on the development of therapeutics against cancer. And in the field of neurodegenerative diseases, the company works on the development of therapeutics against diseases such as Alzheimer's and Parkinson's. Products: VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19. The antibody binds to the spike protein of the virus and blocks its interaction with ACE2 receptors in human cells. It is currently being tested in phase 3 clinical trials. VIR-2703 is a well-tolerated RNA vaccine developed for the prevention of COVID-19. It contains an inactivated form of the virus that stimulates the immune system to produce antibodies against the virus. It is currently being tested in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine developed to cover a broader spectrum of influenza viruses than conventional flu vaccines. The vaccine contains a combination of antibodies against various strains of the influenza virus and was recently investigated in a phase 1/2a clinical trial. Summary: Vir Biotechnology is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company has a proprietary technology platform for antibody identification and collaborates with various partners to utilize this technology for the development of therapeutics against a variety of diseases. The company has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482, as well as research programs in the fields of immuno-oncology and neurodegeneration. The translation is: Vir Biotechnology Inc. is a biopharmaceutical company that focuses on the development of therapeutics to combat infectious diseases. The company was founded in 2016 by George Scangos, former CEO of Biogen, and Bob Nelsen, co-founder of Arch Venture Partners. History: Vir Biotechnology originated from a collaboration between Arch Venture Partners and the biotechnology incubator, The Infectious Disease Research Institute (IDRI), to develop therapeutics against Ebola viruses. In 2016, they founded Vir Biotechnology with an initial capital of $150 million from various investors, including SoftBank and the Bill & Melinda Gates Foundation. The company received an additional capital injection of $250 million in 2018 and went public in the same year. Business model: Vir Biotechnology builds on its proprietary technology platform, which focuses on antibody identification. The company collaborates with various partners, including Biogen and Alnylam Pharmaceuticals, to utilize its technology for the development of therapeutics against infectious diseases such as COVID-19, influenza, rabbit fever, and the Zika virus. Vir Biotechnology also has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482. VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19 and is currently in phase 3 clinical trials. VIR-2703 is an inactive RNA vaccine developed for the prevention of COVID-19 and is currently in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine recently investigated in a phase 1/2a clinical trial. Divisions: Vir Biotechnology has focused on three main divisions: infectious diseases, immuno-oncology therapy, and neurodegenerative diseases. In the field of infectious diseases, the company works on the development of therapeutics against viruses such as COVID-19, respiratory syncytial virus (RSV), West Nile virus, and influenza virus. In the field of immuno-oncology therapy, the company works on the development of therapeutics against cancer. And in the field of neurodegenerative diseases, the company works on the development of therapeutics against diseases such as Alzheimer's and Parkinson's. Products: VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19. The antibody binds to the spike protein of the virus and blocks its interaction with ACE2 receptors in human cells. It is currently being tested in phase 3 clinical trials. VIR-2703 is a well-tolerated RNA vaccine developed for the prevention of COVID-19. It contains an inactivated form of the virus that stimulates the immune system to produce antibodies against the virus. It is currently being tested in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine developed to cover a broader spectrum of influenza viruses than conventional flu vaccines. The vaccine contains a combination of antibodies against various strains of the influenza virus and was recently investigated in a phase 1/2a clinical trial. Summary: Vir Biotechnology is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company has a proprietary technology platform for antibody identification and collaborates with various partners to utilize this technology for the development of therapeutics against a variety of diseases. The company has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482, as well as research programs in the fields of immuno-oncology and neurodegeneration. Vir Biotechnology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Temeljni kapital u detalje

Analiza vlastitog kapitala od Vir Biotechnology

Vlastiti kapital Vir Biotechnology predstavlja vlasnički udjel u poduzeću i izračunava se kao razlika između ukupne imovine i ukupnih obaveza. On odražava preostali zahtjev dioničara na imovinske vrijednosti poduzeća nakon što su sva dugovanja podmirena. Razumijevanje vlastitog kapitala Vir Biotechnology ključno je za procjenu njegovog financijskog zdravlja, stabilnosti i vrijednosti za dioničare.

Usporedba iz godine u godinu

Procjena vlastitog kapitala Vir Biotechnology tijekom uzastopnih godina pruža uvid u rast, profitabilnost i kapitalnu strukturu poduzeća. Rastući vlastiti kapital ukazuje na poboljšanje neto imovine i financijskog zdravlja, dok padajući vlastiti kapital može ukazivati na rastuće dugove ili operativne izazove.

Učinci na investicije

Vlastiti kapital Vir Biotechnology ključni je element za investitore koji utječe na polugu, profil rizika i povrat na vlastiti kapital (ROE) poduzeća. Viši nivo vlastitog kapitala općenito ukazuje na manji rizik i povećanu financijsku stabilnost, čineći poduzeće potencijalno privlačnom investicijskom prilikom.

Interpretacija fluktuacija vlastitog kapitala

Fluktuacije vlastitog kapitala Vir Biotechnology mogu proizlaziti iz različitih faktora, uključujući promjene u neto dobiti, isplatu dividendi i izdavanje ili otkup dionica. Investitori analiziraju ove promjene kako bi ocijenili financijsku izvedbu, operativnu učinkovitost i strateško upravljanje financijama poduzeća.

Česta pitanja o Vir Biotechnology dionici

Koliko iznosi vlastiti kapital od Vir Biotechnology ove godine?

Vir Biotechnology je ove godine ostvario vlastiti kapital od 1,59 milijardi USD.

Koliko je iznosio vlastiti kapital Vir Biotechnology u usporedbi s prošlom godinom?

Vlastiti kapital od Vir Biotechnology je u usporedbi s prošlom godinom porastao/smanjen za −23,47%. pao.

Kakav utjecaj visoki vlasnički kapital ima na investitore Vir Biotechnology?

Visoki vlastiti kapital je za investitore od Vir Biotechnology povoljan jer je to indikator financijske stabilnosti poduzeća i pokazuje njegovu sposobnost da se nosi s rizicima i izazovima.

Koje posljedice ima nizak kapital za investitore od Vir Biotechnology?

Nizak kapital može predstavljati rizik za investitore Vir Biotechnology jer može dovesti poduzeće u slabiju financijsku poziciju i utjecati na njegovu sposobnost da se nosi s rizicima i izazovima.

Kako povećanje kapitala od Vir Biotechnology utječe na tvrtku?

Povećanje kapitala od Vir Biotechnology može ojačati financijsku situaciju poduzeća i poboljšati njegovu sposobnost ulaganja u budućnosti.

Kako smanjenje vlastitog kapitala od Vir Biotechnology utječe na poduzeće?

Smanjenje vlastitog kapitala od Vir Biotechnology može utjecati na financijsku situaciju poduzeća i dovesti do veće ovisnosti o tuđem kapitalu.

Koji su neki od faktora koji utječu na vlastiti kapital od Vir Biotechnology?

Neki faktori koji mogu utjecati na vlastiti kapital od Vir Biotechnology uključuju, između ostalog, dobit, isplate dividendi, povećanje kapitala i preuzimanja.

Zašto je vlastiti kapital od Vir Biotechnology toliko važan za investitore?

Vlastiti kapital od Vir Biotechnology je važan za investitore jer je pokazatelj financijske snage poduzeća i može biti znak koliko je dobro poduzeće sposobno ispuniti svoje financijske obveze.

Koje strateške mjere Vir Biotechnology može poduzeti kako bi promijenio vlastiti kapital?

Da bi promijenila vlastiti kapital, Vir Biotechnology može poduzeti različite mjere poput povećanja dobiti, provođenja povećanja kapitala, smanjenja troškova i preuzimanja drugih poduzeća. Bitno je da tvrtka provede temeljitu provjeru svoje financijske situacije kako bi odredila najbolje strateške mjere za izmjenu svog vlastitog kapitala.

Koliko dividende plaća Vir Biotechnology?

U posljednjih 12 mjeseci Vir Biotechnology je isplatio dividendu u iznosu od . To odgovara prinosu dividende od oko . Za sljedećih 12 mjeseci Vir Biotechnology će vjerojatno isplatiti dividendu u iznosu od 0 USD.

Kolika je dividendna prinosa od Vir Biotechnology?

Trenutni prinos dividende od Vir Biotechnology iznosi .

Kada Vir Biotechnology isplaćuje dividendu?

Vir Biotechnology isplaćuje dividende kvartalno. One se isplaćuju u mjesecima .

Koliko je sigurna dividenda od Vir Biotechnology?

Vir Biotechnology je isplatio dividendu svake godine u posljednjih 0 godina.

Kolika je dividenda od Vir Biotechnology?

Za nadolazećih 12 mjeseci očekuje se isplata dividendi u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

U kojem se sektoru nalazi Vir Biotechnology?

Vir Biotechnology se pripisuje sektoru 'Zdravlje'.

Wann musste ich die Aktien von Vir Biotechnology kaufen, um die vorherige Dividende zu erhalten?

Da bi primili posljednju dividendu od Vir Biotechnology od 06. 10. 2024. u iznosu od 0 USD, trebali ste imati dionicu u portfelju prije Ex-dana 06. 10. 2024..

Kada je Vir Biotechnology isplatio posljednju dividendu?

Posljednja isplata dividende izvršena je 06. 10. 2024..

Kolika je bila dividenda Vir Biotechnology u godini 2023?

U godini 2023 su od Vir Biotechnology 0 USD isplaćene kao dividende.

U kojoj valuti Vir Biotechnology isplaćuje dividendu?

Dividende od Vir Biotechnology isplaćuju se u USD.

Aktiensparpläne nude atraktivnu mogućnost za investitore za dugoročno stvaranje imovine. Jedna od glavnih prednosti je tzv. efekt prosječenja troškova: investirajući redovito fiksni iznos u dionice ili dioničke fondove, automatski se kupuje više udjela kada su cijene niske, a manje kada su visoke. To može dovesti do povoljnijeg prosječnog cijene po udjelu tijekom vremena. Osim toga, Aktiensparpläne omogućavaju i malim investitorima pristup skupim dionicama, jer mogu sudjelovati već s malim iznosima. Redovita investicija također promiče discipliniranu strategiju ulaganja i pomaže izbjeći emocionalne odluke, poput impulzivne kupnje ili prodaje. Pored toga, investitori profitiraju od potencijalnog povećanja vrijednosti dionica kao i od isplata dividendi koje mogu biti reinvestirane, što pojačava učinak kamatnog kamata i time rast uloženog kapitala.

Andere Kennzahlen von Vir Biotechnology

Naša analiza dionica Vir Biotechnology Prihod uključuje važne financijske pokazatelje kao što su prihod, dobit, P/E omjer, P/S omjer, EBIT, kao i informacije o dividendi. Također, razmatramo aspekte poput dionica, tržišne kapitalizacije, dugova, vlastitog kapitala i obveza Vir Biotechnology Prihod. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama nudimo opsežne analize: